Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 31, 2024
Daily News
January 31, 2024
- Axcelead DDP Looks to Lift Overseas Sales Ratio to 80%: President
January 31, 2024
- Japan to Revise Ad Guidelines to Address GLP-1 Use for Cosmetic Weight Loss
January 31, 2024
- Teva Takeda JVs Curb Shipments of 8 Products in Quake Fallout
January 31, 2024
- Gilead Files Trodelvy for Triple-Negative Breast Cancer in Japan
January 31, 2024
- US FDA Approves Additional CIDP Use for Takeda’s Gammagard Liquid
January 31, 2024
- Takeda’s Hyqvia Nabs European Approval for CIDP Maintenance Therapy
January 31, 2024
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…